ABCL News and Press, AbCellera Biologics Inc. From 05/10/22

AbCellera Biologics Inc. (ABCL) Q1 2022 Results Conference Call May 10, 2022 05:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fau...

AbCellera Biologics press release (NASDAQ:ABCL): Q1 GAAP EPS of $0.54. Revenue of $317M (+56.4% Y/Y). Shares +4.07%. For further details see: AbCellera Biologics GAAP EPS of $0.54, revenue of $317M

Total revenue of $317 million, compared to $203 million in Q1 2021 Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021 Net earnings of $0.59 per share on a basic and $0.54 on a diluted basis compared to $0.43 (basic) and $0....

The NASDAQ is finally in formal bear market territory, although, as high growth investors fully know, we have been in a brutal bear market since at least November of 2021. My aggressive growth portfolio has not been spared the extreme pain; however, I am confident in my positions once...

AbCellera (NASDAQ:ABCL) has expanded a collaboration with Empirico from five to seven targets to identify antibodies against them. Also, AbCellera now has a co-development option on a program-by-program basis. Financial terms of the expanded agreement were not disclosed. Empirico's Precision ...

Collaboration expanded from five to seven targets and provides AbCellera the option to co-develop therapeutic programs in partnership with Empirico AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have expanded their strategic m...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022, in Toronto, Canada at 6:30 a.m. Pacific Time (9:30 a.m. Eastern Time). A live audio webcast of the pre...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbCellera Biologics ( ABCL ): Impressive sales growth is very promising for this firm and its antibody discovery platform. SIGA Technologies ( SIGA ): Improved profitability and a remarkable ROE make it very ...

Issuing a health advisory on Monday, the Centers for Disease Control and Prevention (CDC) listed the COVID-19 antivirals developed by Pfizer (NYSE:PFE) and Gilead (NASDAQ:GILD) as preferred therapies to treat non-hospitalized patients who are at a high risk of developing the severe ...

AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly. The company recently announced an internally developed T-Cell engager program that it is looking to partner, likely at attractive terms for AbCellera, ...